Compare EAT & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EAT | PTCT |
|---|---|---|
| Founded | 1975 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.5B |
| IPO Year | 1994 | 2006 |
| Metric | EAT | PTCT |
|---|---|---|
| Price | $147.05 | $66.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 16 |
| Target Price | ★ $184.59 | $80.94 |
| AVG Volume (30 Days) | ★ 1.0M | 970.9K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 144.71 | ★ 264.48 |
| EPS | 5.03 | ★ 7.78 |
| Revenue | ★ $5,384,200,000.00 | $264,734,000.00 |
| Revenue This Year | $9.02 | N/A |
| Revenue Next Year | $5.45 | $19.30 |
| P/E Ratio | $30.11 | ★ $8.27 |
| Revenue Growth | 21.95 | ★ 36.19 |
| 52 Week Low | $100.30 | $35.95 |
| 52 Week High | $187.12 | $87.50 |
| Indicator | EAT | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 46.70 |
| Support Level | $133.70 | $61.43 |
| Resistance Level | $154.19 | $69.29 |
| Average True Range (ATR) | 5.28 | 2.46 |
| MACD | 1.46 | 0.28 |
| Stochastic Oscillator | 71.74 | 49.11 |
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.